Drug Approval | May 27, 2022
USFDA approves Omeprazole capsules to prevent heartburn
Perrigo expects to launch Omeprazole Minis later this year
Perrigo expects to launch Omeprazole Minis later this year
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The production suspension impacts commercial and clinical trial supply
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore formulation platform
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Subscribe To Our Newsletter & Stay Updated
